利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

550 条记录 (耗时 0.015 秒)

    Enzyme-mediated synthesis of esters and lactones
    93.
    发明授权
    Enzyme-mediated synthesis of esters and lactones 失效
    酶介导的酯和内酯的合成

    公开(公告)号：US4451565A

    公开(公告)日：1984-05-29

    申请号：US350519

    申请日：1982-02-19

    申请人： Ian Gatfield ,  Theodor Sand

    发明人： Ian Gatfield ,  Theodor Sand

    IPC分类号： C12P7/40 ,  C12P7/42 ,  C12P7/62 ,  C12P17/02 ,  C12P17/04 ,  C12P17/00 ,  C12P7/00 ,  C12R1/785

    CPC分类号： C12P17/04 ,  C12P7/62 ,  Y10S435/931

    摘要： In the enzyme-mediated synthesis of an ester or lactone from at least one carboxylic acid of the formulaR--CH.sub.2 --CH.sub.2 --COOHwhereinR is a hydrogen atom, or a hydrocarbon radical which has 1 to 21 carbon atoms and which can be optionally substituted by hydroxyl groups or alkoxy groups with 1 to 10 carbon atoms,with at least one primary or secondary alcohol having 1 to 15 carbon atoms, the improvement which comprises employing as the enzyme the esterase from Mucor miehei and effecting the synthesis in the absence of water. Advantageously, the synthesis is effected at about room temperature, the mol ratio of carboxylic acid to alcohol is from about 1:1 to 1:1.1, and the enzyme is used in a quantity of about 3 to 20% by weight of the carboxylic acid. The absence of water facilitates recovery, as by distillation.

    摘要翻译： 在酶介导的由至少一种式R-CH 2 -CH 2 -COOH的羧酸（其中R是氢原子）或具有1至21个碳原子的烃基的酯或内酯的合成中，其可以是任选的 由具有1-10个碳原子的羟基或烷氧基取代，至少一个具有1至15个碳原子的伯醇或仲醇，其改进包括使用来自Mucor miehei的酯酶并在不存在下进行合成 水。 有利地，合成在约室温下进行，羧酸与醇的摩尔比为约1:1至1:1.1，酶的用量为羧酸的约3-20重量％ 。 没有水有助于回收，如通过蒸馏。

    Synthesis of ascorbic acid from lactose
    94.
    发明授权
    Synthesis of ascorbic acid from lactose 失效
    从乳糖合成抗坏血酸

    公开(公告)号：US4259443A

    公开(公告)日：1981-03-31

    申请号：US47937

    申请日：1979-06-12

    申请人： James P. Danehy

    发明人： James P. Danehy

    IPC分类号： C07D307/62 ,  C07H7/033 ,  C07H15/04 ,  C12P7/58 ,  C12P7/60 ,  C12P17/04 ,  C12N9/04

    CPC分类号： C07H15/04 ,  C07D307/62 ,  C07H7/033 ,  C12P17/04 ,  C12P7/58 ,  C12P7/60

    摘要： A method of synthesizing vitamin C (ascorbic acid) directly from the hydrolysis products of lactose. Lactose, economically obtained from whey, undergoes hydrolysis with a warm aqueous slurry of lactase to produce D-galactose and D-glucose. Preparing the methyl glycosides of these two sugars protects a labile C-O linkage during the oxidation of the sugars to D-galacturonic acid and D-glucuronic acid. The mixture of these acids, after the removal of the methyl group through hydrolysis, undergoes reduction with gaseous hydrogen in the presence of an Adams catalyst or Raney nickel to produce a mixture of L-gulonic acid and L-galactonic acid. Removing the water from these acids forces their conversion into the corresponding lactones. Because of the applicable rate constants, adding water to the lactones does not result in their rapid reconversion to the acids. Accordingly, they can then undergo oxidation, in the presence of an enzyme obtained from pea seeds, to L-ascorbic acid.

    摘要翻译： 从乳糖水解产物中直接合成维生素C（抗坏血酸）的方法。 从乳清经济地获得的乳糖用乳糖酶的温水性浆液进行水解以产生D-半乳糖和D-葡萄糖。 制备这两种糖的甲基糖苷可保护糖在D-半乳糖醛酸和D-葡萄糖醛酸氧化过程中不稳定的C-O键。 这些酸的混合物在通过水解除去甲基后，在亚当斯催化剂或阮内镍存在下用气态氢还原，生成L-古洛糖酸和L-半乳糖酸的混合物。 从这些酸中去除水会迫使其转化成相应的内酯。 由于适用的速率常数，向内酯中加入水不会导致其快速再转化为酸。 因此，它们可以在从豌豆种子获得的酶的存在下进行氧化，进行L-抗坏血酸。

    Sesquiterpene derivatives having anti-complementary activity
    95.
    发明授权
    Sesquiterpene derivatives having anti-complementary activity 失效
    倍半萜衍生物具有抗互补活性

    公开(公告)号：US4229466A

    公开(公告)日：1980-10-21

    申请号：US906300

    申请日：1978-05-15

    申请人： Wasei Miyazaki ,  Hirotsugu Kaise ,  Yoshimasa Nakano ,  Taketoshi Izawa ,  Yasuo Oshiro ,  Masanao Shinohara

    发明人： Wasei Miyazaki ,  Hirotsugu Kaise ,  Yoshimasa Nakano ,  Taketoshi Izawa ,  Yasuo Oshiro ,  Masanao Shinohara

    IPC分类号： C07D307/94 ,  C07D493/10 ,  C07D493/20 ,  C12P17/04 ,  A61K31/335 ,  A61K31/34 ,  C07D307/77 ,  C07D307/92

    CPC分类号： C07D307/94 ,  C07D493/10 ,  C12P17/04

    摘要： A sesquiterpene derivative expressed by the general formula (I): ##STR1## wherein R.sup.1 represents a hydrogen atom, a lower alkyl group or a lower alkanoyl group; R.sup.2 and R.sup.3, which may be the same or different, each represents a formyl group, a hydroxymethyl group, a hydroxyl group, a carboxyl group, a lower alkanoyloxymethyl group, or a group of the formula --CH.dbd.CR.sup.7 R.sup.8, wherein R.sup.7 and R.sup.8, which may be the same or different, each represents a hydrogen atom, a cyano group, a lower alkoxycarbonyl group or a carboxyl group, or R.sup.2 and R.sup.3 may combine to form a lactone ring of the formula ##STR2## in which R.sup.9 represents a hydrogen atom or a hydroxyl group; R.sup.4 and R.sup.6, which may be the same or different, each represents a hydroxyl group or a lower alkanoyloxy group; R.sup.5 represents a hydrogen atom; R.sup.4 and R.sup.5 may together form an oxo group (.dbd.O); and R.sup.4 and R.sup.6 may combine to form a lower alkylidenedioxy group, the pharmaceutically acceptable salts thereof, processes for the production of the compounds of the general formula (I) and the salts thereof, pharmaceutical composition containing the compounds of the general formula (I) and the salts thereof, and method of use of the compounds of the general formula (I) and the salts thereof.

    摘要翻译： 由通式（I）表示的倍半萜衍生物：其中R 1表示氢原子，低级烷基或低级烷酰基; R2和R3可以相同或不同，分别表示甲酰基，羟甲基，羟基，羧基，低级烷酰氧基甲基或式-CH = CR7R8的基团，其中R7和R8 可以相同或不同，各自表示氢原子，氰基，低级烷氧基羰基或羧基，或者R 2和R 3可以结合形成式“IMAGE”的内酯环，其中R 9表示 氢原子或羟基; R 4和R 6可以相同或不同，分别表示羟基或低级烷酰氧基; R5代表氢原子; R4和R5可以一起形成氧代基（= O）; 并且R4和R6可以结合形成低级亚烷基二氧基，其药学上可接受的盐，通式（I）化合物及其盐的制备方法，含有通式（I）化合物的药物组合物， 及其盐，以及通式（I）的化合物及其盐的使用方法。

    Fermentation process for the production of (+)-2-(5.beta.-n-butyl-4.beta.-hydroxy-2-oxo-tetrahydrofuran-3.beta.-yl) -2.alpha.-methylacetic acid
    96.
    发明授权
    Fermentation process for the production of (+)-2-(5.beta.-n-butyl-4.beta.-hydroxy-2-oxo-tetrahydrofuran-3.beta.-yl) -2.alpha.-methylacetic acid 失效
    （+） - 2-（5β-正丁基-4β-羟基-2-氧代 - 四氢呋喃-3β-基）-2α-甲基乙酸的生产的发酵方法

    公开(公告)号：US4178213A

    公开(公告)日：1979-12-11

    申请号：US864473

    申请日：1977-12-27

    申请人： David C. Aldridge ,  Roger Bowling ,  John C. Swait

    发明人： David C. Aldridge ,  Roger Bowling ,  John C. Swait

    IPC分类号： C07D307/33 ,  C12P17/04 ,  C12D13/00

    CPC分类号： C07D307/33 ,  C12P17/04 ,  Y10S435/933

    摘要： The invention concerns a fermentation process for the production of (+)-2-(5.beta.-n-butyl-4.beta.-hydroxy-2-oxo-tetrahydrofuran-3.beta.-yl)-2.alpha.-methylacetic acid, which compound has useful ulcer-healing properties. The process is characterised by cultivating an organism known to produce dihydrocanadensolide, such as Penicillium canadense, under generally conventional conditions and then extracting the culture filtrate at a pH in the range pH 3.0-7.0 with a suitable solvent, such as ethyl acetate, and then evaporating the extract to dryness. In a preferred embodiment the extraction is carried out on the culture filtrate at pH 4.0-4.5.

    摘要翻译： 本发明涉及产生（+） - 2-（5β-正丁基-4β-羟基-2-氧代 - 四氢呋喃-3β-基）-2α-甲基乙酸的发酵方法，该化合物具有 有用的溃疡愈合属性。 该方法的特征在于在一般常规条件下培养已知生产二氢甘油多异丙二醇（例如青霉菌）的生物，然后用合适的溶剂如乙酸乙酯在pH3.0-7.0的pH范围内提取培养滤液，然后 将提取物蒸发至干燥。 在优选的实施方案中，在pH 4.0-4.5的培养滤液上进行萃取。

    COMPOSITIONS AND METHODS FOR PRODUCTION OF GLUCOSE OXIDATION PRODUCTS
    98.
    发明申请
    COMPOSITIONS AND METHODS FOR PRODUCTION OF GLUCOSE OXIDATION PRODUCTS 有权

    公开(公告)号：US20230121990A1

    公开(公告)日：2023-04-20

    申请号：US17905736

    申请日：2021-03-06

    申请人： Solugen, Inc.

    发明人： Toni M. Lee ,  Shuai Qian ,  Brian F. Fisher ,  Sarah Downing ,  Gaurab Chakrabarti ,  Sean Hunt

    IPC分类号： C12P17/06 ,  C12P17/04 ,  C12N9/04 ,  C12N9/08 ,  C12N9/02

    摘要： A chemoenzymatic process for the preparation of an oxidized glucose product comprising contacting D-glucose with an enzyme selected from the group consisting essentially of galactose oxidase (GAO), glucose oxidase (GOX), polysaccharide monooxygenase, catalase, animal peroxidase, periplasmic aldehyde oxidase (Pao), unspecific peroxygenase (UPO), lactoperoxidase (LPO), myeloperoxidase (MPO), eosinophil peroxidase (EPO), thyroid peroxidase (TPO), ovoperoxidase, salivary peroxidase, vanadium haloperoxidase, non-mammalian vertebrate peroxidase (POX), peroxidasin (Pxd), bacterial peroxicin (Pxc), invertebrate peroxinectin (Pxt), short peroxidockerin (PxDo), alpha-dioxygenase (aDox), dual oxidase (DuOx), prostaglandin H synthase (PGHS), cyclooxygenase (CyOx), linoleate diol synthase (LDS), variants thereof, and combinations thereof under conditions suitable for the formation of an oxidized intermediate; and contacting the oxidized intermediate with a metal catalyst to form an oxidized glucose product.